Assessing Conmed: Insights From 6 Financial Analysts
Portfolio Pulse from Benzinga Insights
Conmed (NYSE:CNMD) has received mixed ratings from analysts, with a majority being bullish. The average 12-month price target is $87.83, a decline from previous estimates. Analysts have adjusted their ratings and price targets in response to market conditions. Conmed's financial performance shows strong net margins and ROE, but its revenue growth lags behind industry peers.
October 04, 2024 | 6:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Conmed has received a mix of bullish and somewhat bullish ratings from analysts, with an average 12-month price target of $87.83, down 7.55% from prior estimates. Analysts have adjusted their ratings and price targets, reflecting market conditions and company performance.
The majority of analysts are bullish on Conmed, but the average price target has decreased, indicating tempered expectations. The adjustments in ratings and price targets suggest a neutral short-term impact as analysts react to market conditions and company performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100